Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study-Reference-Cited by-同舟云学术

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Published:2018-12 Issue:12 Volume:19 Page:1654-1667
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Solomon Benjamin J,Besse Benjamin,Bauer Todd M,Felip Enriqueta,Soo Ross A,Camidge D Ross,Chiari Rita,Bearz Alessandra,Lin Chia-Chi,Gadgeel Shirish M,Riely Gregory J,Tan Eng Huat,Seto Takashi,James Leonard P,Clancy Jill S,Abbattista Antonello,Martini Jean-François,Chen Joseph,Peltz Gerson,Thurm Holger,Ou Sai-Hong Ignatius,Shaw Alice T

Publisher

Elsevier BV

Subject

Oncology

Reference26 articles.

1. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer;Koivunen;Clin Cancer Res,2008

2. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer;Rikova;Cell,2007

3. RET, ROS1 and ALK fusions in lung cancer;Takeuchi;Nat Med,2012

4. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014

5. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer;Peters;N Engl J Med,2017

Cited by 606 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape;Cancer Treatment Reviews;2024-11

2. Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification;Lung Cancer;2024-09

3. ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance;JTO Clinical and Research Reports;2024-09

4. Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer;Targeted Oncology;2024-08-10

5. Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations;Cancer Reports;2024-08